168,000 Shares in Integra LifeSciences Holdings Corporation $IART Purchased by Hussman Strategic Advisors Inc.

Hussman Strategic Advisors Inc. purchased a new stake in shares of Integra LifeSciences Holdings Corporation (NASDAQ:IART) in the 3rd quarter, according to its most recent filing with the Securities & Exchange Commission. The firm purchased 168,000 shares of the life sciences company’s stock, valued at approximately $2,407,000. Hussman Strategic Advisors Inc. owned approximately 0.22% of Integra LifeSciences at the end of the most recent quarter.

Other hedge funds have also bought and sold shares of the company. Amalgamated Bank increased its holdings in shares of Integra LifeSciences by 3.8% during the 3rd quarter. Amalgamated Bank now owns 19,809 shares of the life sciences company’s stock valued at $284,000 after purchasing an additional 728 shares in the last quarter. Wealth Enhancement Advisory Services LLC increased its holdings in Integra LifeSciences by 6.4% in the third quarter. Wealth Enhancement Advisory Services LLC now owns 14,200 shares of the life sciences company’s stock valued at $205,000 after buying an additional 848 shares in the last quarter. GAMMA Investing LLC raised its position in shares of Integra LifeSciences by 55.3% in the third quarter. GAMMA Investing LLC now owns 2,565 shares of the life sciences company’s stock worth $37,000 after acquiring an additional 913 shares during the period. Osaic Holdings Inc. boosted its stake in shares of Integra LifeSciences by 36.6% during the 2nd quarter. Osaic Holdings Inc. now owns 4,119 shares of the life sciences company’s stock worth $51,000 after acquiring an additional 1,104 shares in the last quarter. Finally, Commonwealth of Pennsylvania Public School Empls Retrmt SYS grew its position in shares of Integra LifeSciences by 8.0% during the 2nd quarter. Commonwealth of Pennsylvania Public School Empls Retrmt SYS now owns 17,159 shares of the life sciences company’s stock valued at $211,000 after acquiring an additional 1,278 shares during the period. Hedge funds and other institutional investors own 84.78% of the company’s stock.

Integra LifeSciences Trading Down 3.6%

Shares of IART opened at $11.13 on Wednesday. Integra LifeSciences Holdings Corporation has a 52-week low of $10.87 and a 52-week high of $27.13. The stock has a market cap of $866.94 million, a PE ratio of -1.72 and a beta of 1.02. The firm’s fifty day moving average is $12.73 and its two-hundred day moving average is $13.39. The company has a quick ratio of 1.80, a current ratio of 3.14 and a debt-to-equity ratio of 1.73.

Integra LifeSciences (NASDAQ:IART) last posted its quarterly earnings results on Thursday, October 30th. The life sciences company reported $0.54 earnings per share for the quarter, topping the consensus estimate of $0.43 by $0.11. The firm had revenue of $402.06 million for the quarter, compared to the consensus estimate of $414.31 million. Integra LifeSciences had a negative net margin of 30.15% and a positive return on equity of 14.06%. The company’s revenue for the quarter was up 5.6% on a year-over-year basis. During the same period last year, the firm posted $0.41 earnings per share. Integra LifeSciences has set its Q4 2025 guidance at 0.790-0.840 EPS and its FY 2025 guidance at 2.190-2.240 EPS. Research analysts forecast that Integra LifeSciences Holdings Corporation will post 2.45 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

IART has been the subject of a number of analyst reports. Citigroup reduced their price target on Integra LifeSciences from $12.00 to $11.00 and set a “sell” rating for the company in a report on Friday, October 31st. Truist Financial reaffirmed a “hold” rating and set a $13.00 target price (down from $15.00) on shares of Integra LifeSciences in a research note on Monday, November 3rd. Weiss Ratings reiterated a “sell (e+)” rating on shares of Integra LifeSciences in a research report on Monday, December 29th. Wall Street Zen raised shares of Integra LifeSciences from a “hold” rating to a “buy” rating in a report on Saturday, November 8th. Finally, JPMorgan Chase & Co. increased their price objective on shares of Integra LifeSciences from $12.00 to $13.00 and gave the company an “underweight” rating in a report on Friday, October 31st. Two analysts have rated the stock with a Buy rating, two have assigned a Hold rating and three have given a Sell rating to the stock. According to data from MarketBeat, Integra LifeSciences has an average rating of “Reduce” and a consensus target price of $15.00.

Insider Buying and Selling at Integra LifeSciences

In related news, Director Jeffrey A. Graves purchased 9,000 shares of the company’s stock in a transaction dated Wednesday, November 5th. The stock was acquired at an average cost of $11.35 per share, for a total transaction of $102,150.00. Following the completion of the transaction, the director directly owned 41,086 shares of the company’s stock, valued at approximately $466,326.10. This trade represents a 28.05% increase in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link. 3.54% of the stock is currently owned by corporate insiders.

Integra LifeSciences Company Profile

Integra LifeSciences Corporation is a global medical technology company specializing in products and innovations for neurosurgery, regenerative medicine and reconstructive procedures. The company develops and markets surgical instruments, implants and advanced wound care solutions designed to support tissue repair and functional recovery. Its product portfolio includes collagen-based matrices, dural substitutes, hemostatic agents and specialized spinal and peripheral fixation devices.

Founded in 1989 and headquartered in Plainsboro, New Jersey, Integra has expanded its capabilities through targeted acquisitions and internal research efforts.